Straits Times Index
3,322.61 -3.67 (-0.11%) Nikkei
39,413.13 +239.98 (+0.61%) Hang Seng
17,934.63 -138.27 (-0.77%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,936.93 +1,672.15 (+2.77%) CMC Crypto 200
1,284.76 +35.64 (+2.86%)
APLS240621P00025000
- Simply Wall St.
Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week
While Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shareholders are probably generally happy, the stock hasn't had...
- Zacks
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
- GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that SYFOVRE® (pegcetacoplan injection) preserved visual function at 36 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). These positive data from the GALE long-term ext
